Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.

Scheiter A, Mellin S, Keil F, Meier J, Heudobler D, Brummer C, Einhell S, Zwicker B, Wutzlhofer E, Hierl F, Klemm S, Lüftl E, Schneider T, Perl M, Klier-Richter M, Immel A, Kaltofen T, Grube M, Bumes E, Seitz S, Schulz C, Haferkamp S, Drexler K, Troeger A, Steger F, Schlosser-Hupf S, Tews HC, Kandulski A, Wohlfart K, Erber R, Schönbuchner I, Lessel D, Schnabel MJ, Sedlmeier AM, Klinkhammer-Schalke M, Maurer J, Calvisi DF, Pukrop T, Kaiser U, Hirsch D, Dietmaier W, Evert M, Lüke F, Utpatel K

Open source

DOI
10.1186/s12916-026-04636-y
Published
2026 Jan 14
Container
BMC medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12916-026-04636-y,
  title = {Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.},
  author = {Scheiter A and Mellin S and Keil F and Meier J and Heudobler D and Brummer C and Einhell S and Zwicker B and Wutzlhofer E and Hierl F and Klemm S and Lüftl E and Schneider T and Perl M and Klier-Richter M and Immel A and Kaltofen T and Grube M and Bumes E and Seitz S and Schulz C and Haferkamp S and Drexler K and Troeger A and Steger F and Schlosser-Hupf S and Tews HC and Kandulski A and Wohlfart K and Erber R and Schönbuchner I and Lessel D and Schnabel MJ and Sedlmeier AM and Klinkhammer-Schalke M and Maurer J and Calvisi DF and Pukrop T and Kaiser U and Hirsch D and Dietmaier W and Evert M and Lüke F and Utpatel K},
  year = {2026},
  journal = {BMC medicine},
  doi = {10.1186/s12916-026-04636-y},
  url = {https://doi.org/10.1186/s12916-026-04636-y}
}

RIS

TY  - JOUR
TI  - Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.
AU  - Scheiter A
AU  - Mellin S
AU  - Keil F
AU  - Meier J
AU  - Heudobler D
AU  - Brummer C
AU  - Einhell S
AU  - Zwicker B
AU  - Wutzlhofer E
AU  - Hierl F
AU  - Klemm S
AU  - Lüftl E
AU  - Schneider T
AU  - Perl M
AU  - Klier-Richter M
AU  - Immel A
AU  - Kaltofen T
AU  - Grube M
AU  - Bumes E
AU  - Seitz S
AU  - Schulz C
AU  - Haferkamp S
AU  - Drexler K
AU  - Troeger A
AU  - Steger F
AU  - Schlosser-Hupf S
AU  - Tews HC
AU  - Kandulski A
AU  - Wohlfart K
AU  - Erber R
AU  - Schönbuchner I
AU  - Lessel D
AU  - Schnabel MJ
AU  - Sedlmeier AM
AU  - Klinkhammer-Schalke M
AU  - Maurer J
AU  - Calvisi DF
AU  - Pukrop T
AU  - Kaiser U
AU  - Hirsch D
AU  - Dietmaier W
AU  - Evert M
AU  - Lüke F
AU  - Utpatel K
PY  - 2026
JO  - BMC medicine
DO  - 10.1186/s12916-026-04636-y
UR  - https://doi.org/10.1186/s12916-026-04636-y
ER  - 

APA

A, S., S, M., F, K., J, M., D, H., C, B., S, E., B, Z., E, W., F, H., S, K., E, L., T, S., M, P., M, K., A, I., T, K., M, G., E, B., S, S., C, S., S, H., K, D., A, T., F, S., S, S., HC, T., A, K., K, W., R, E., I, S., D, L., MJ, S., AM, S., M, K., J, M., DF, C., T, P., U, K., D, H., W, D., M, E., F, L., & K, U. (2026). Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.. BMC medicine. https://doi.org/10.1186/s12916-026-04636-y

Source records